[Effectiveness and tolerance of a combination of fluticasone and salmeterol in patients with obstructive airway diseases. DUO Study Group].
The purpose of this open multicentre study was to evaluate prospectively the efficacy and safety of a combination of fluticasone (250 micrograms b.i.d.) and salmeterol (50 micrograms b.i.d.), both given by a metered dose inhaler, in 413 patients (mean age [+/- SEM] 46.9 +/- 0.7 years) suffering from obstructive airways disease (FEV1 % predicted 73 +/- 1.1%) for 10 +/- 0.5 years. 8 weeks of therapy with both drugs improved FEV1 and peak expiratory flow by 24 +/- 3.1% and 27 +/- 2.7%, respectively. Daytime and nocturnal symptoms, rescue beta 2 agonist use, days off work, and symptoms during working hours decreased. Similarly, the quality of sleep improved (p < 0.001, all comparisons to baseline). More than 80% of patients and physicians independently classified the study medication as superior to their previous therapy. Adverse events possibly, likely or definitely related to the study medication were seen in 9% of patients. In conclusion, an inhaled corticosteroid (fluticasone) together with an inhaled long-acting beta 2 agonist (salmeterol) is an effective and well tolerated therapy in patients with obstructive airways disease.
Wiewrodt
R
R
III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz.
Dauletbaev
N
N
Buhl
R
R
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol
Wirksamkeit und Verträglichkeit einer Kombination von Fluticason und Salmeterol bei Patienten mit obstruktiver Atemwegserkrankung. DUO-Studiengruppe.